

Perkins Coie Represents TRACT Therapeutics in Strategic Collaboration with Taiwan Bio

CHICAGO (December 14, 2023)—Perkins Coie is pleased to have represented TRACT Therapeutics, a clinical stage biotechnology company, in its strategic collaboration deal to advance cellular therapy with Taiwan Bio, a one-stop, total solution cell therapy contract development and manufacturing organization. For more information, please see TRACT Therapeutics' press release [here](#).

The new strategic collaboration between Taiwan Bio and TRACT Therapeutics will work to advance cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplants. The partners will launch a multi-center Phase 2 clinical trial investigating the reduction of immunosuppressant drugs in living donor kidney transplant recipients in both the United States and Taiwan.

The Perkins Coie team that advised TRACT Therapeutics included partners [Steven Ducommun](#) and Mark Wicker, and associate [Alina Litoshyk](#).

Perkins Coie is a leading global law firm, dedicated to helping the world's most innovative companies solve the legal and business challenges of tomorrow. Learn about our work and values [here](#).

Media Inquiries: Please email [Justin Cole](#), Head of Media Relations.

Contact



[Steven E. Ducommun](#)

Partner

SDucommun@perkinscoie.com [312.324.8404](tel:312.324.8404)



Mark R. Wicker

Partner

MWicker@perkinscoie.com [858.720.5733](tel:858.720.5733)



Alina Litoshyk Adams

Counsel

AAadams@perkinscoie.com [858.720.5740](tel:858.720.5740)

Explore more in

[Corporate Law](#)

Media inquiries